YujinHoshidaMDPhD

Hepatology & Liver Transplantation

Professor of Internal Medicine, Director of Liver Tumor Translational Research

Dr. Hoshida is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Recruiting
Roles: Contact
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Start of enrollment: 2023 May 10
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Erlotinib for Hepatocellular Carcinoma Chemoprevention Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
EGCG for Hepatocellular Carcinoma Chemoprevention Start of enrollment: 2024 Aug 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

29 citations
Risk stratification and early detection biomarkers for precision HCC screening.
Yi-Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
Hepatology. 2023-07-01
Precision HCC Surveillance: It Is All in the Number (Needed).
Amit G Singal, Neehar D Parikh, Yujin Hoshida
Digestive Diseases and Sciences. 2023-03-01
22 citations
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Natascha Roehlen, Marion Muller, Zeina Nehme, Emilie Crouchet, Frank Jühling
Journal of Hepatology. 2023-02-01

MedBlog Cancer; Digestive; Discovery Taking Aim at Fatty Liver, Cancer With New Blood TestSeptember 7th, 2022
A Simple Blood Test Reliably Predicts the Development of Liver Cancer – Healing PracticeJune 24th, 2022
UTSW Researchers Identify a New Biomarker to Assess Your Risk of Liver CancerJune 6th, 2022
Join now to see all